Novartis Ag

Other

Irm LLC

Bernhard Hubert Geierstanger

Tetsuo Uno

Weijia Ou

Jan Grunewald

Xing Wang

Yongqin Wan

Yunho Jin

Susan E Cellitti

Mark Knuth

Glen Spraggon

Siew Ho Schleyer

Catrin Finner

Shailaja Kasibhatla

Stuart Licht

Andreas Loew

Matthew T Burger

Shifeng Pan

Steven Lee Bender

Thomas Huber

Scott Glaser

Tinya Abrams

Shari Lynn Caplan

Michael P Cooke

Steven Bruce Cohen

Brian R Boettcher

Kathrin Tissot

John Trauger

William Mallet

Norio Hamamatsu

Kathrin Ulrike Tissot-Daguette

Matthew John Meyer

Stephen Craig Weldon

Douglas S Daniels

Dylan L Daniel

Sarah Rue

Michael DiDonato

Anthony E Boitano

Shelly Meeusen

Xueshi Hao

Anna Galkin

Ben Wen

Sabine Rottmann

Tiffany Crossgrove

Tracy Charlton

Tobias Junt

Hsien-Po Chiu

Carolina Nicole Simpson

Si Tuen Lee-Hoeflich

HongNgoc Thi Pham

Tom Yao-Hsiang Wu

Badry Bursulaya

Timothy Z Hoffman

Alex Cortez

This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Anti-CCR7 antibody drug conjugates

The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Antibody drug conjugates for ablating hematopoietic stem cells

The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

CKIT antibody drug conjugates

The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.

Specific sites for modifying antibodies to make immunoconjugates

The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.

Methods of treating immune related disorders using antibody-cytokine engrafted compositions

Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

Antibody conjugates comprising toll-like receptor agonist

Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Cytotoxic peptides and conjugates thereof

The present invention relates to the identification of dual function fusion proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating metabolic, cardiovascular, and endocrine conditions related to glucose and/or lipid homeostasis.

Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins

Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Antibody cytokine engrafted compositions and methods of use for immunoregulation

Growing community of inventors

Solana Beach, CA, United States of America

Bernhard Hubert Geierstanger